Oncolytics Biotech® to Participate in BIO Investor Forum Digital

On October 7, 2020 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) reported that the Company will be participating in the BIO Investor Forum Digital, which is taking place virtually from October 13-15, 2020 (Press release, Oncolytics Biotech, OCT 7, 2020, View Source [SID1234568182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s profile for the forum is available here. Registered attendees will be able to view an on-demand corporate overview provided by President and Chief Executive Officer Dr. Matt Coffey. Company management will also be participating in one-on-one investor meetings at the forum. To schedule a meeting, please submit a meeting request on the forum website, or email [email protected].

Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement

On October 7, 2020 Exact Sciences Corp. (Nasdaq: EXAS) and Pfizer Inc. (NYSE: PFE) reported an extension and amendment of their agreement to promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer (Press release, Exact Sciences, OCT 7, 2020, View Source [SID1234568180]). Under terms of the nationwide agreement, Pfizer will continue to provide marketing and related support for Cologuard and join Exact Sciences’ efforts to educate patients, physicians, and health systems about Cologuard.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The COVID-19 pandemic has highlighted the need for convenient, accurate cancer testing options. Outcomes can be dramatically improved if colorectal cancer is caught in early stages, and with more than an estimated one million screening colonoscopies missed this year, there is an urgent need to increase screening rates.1 Cologuard is an accurate, at-home colon cancer screening option and is uniquely positioned to support screening during this time and after the pandemic abates.

"We’re thrilled to continue working with Pfizer to increase screening rates with Cologuard, especially during this critical time," said Kevin Conroy, chairman and CEO of Exact Sciences. "Over the past two years, Pfizer has shown incredible commitment to Exact Sciences’ goal of eradicating colorectal cancer by helping detect the disease at its earliest, most treatable stages. The talented Exact Sciences team is excited to continue joining forces with Pfizer to help improve screening rates among the 46 million unscreened Americans."

In the two years since the partnership began, more than 3 million people were screened with Cologuard and more than 90,000 healthcare providers ordered Cologuard for the first time. The combined teams have also introduced several new direct-to-consumer marketing campaigns and worked with dozens of large health systems to improve colorectal cancer screening rates.

"Now more than ever, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency. This partnership is a testament to that purpose, and Pfizer is incredibly proud of the work we have done with Exact Sciences to raise colorectal cancer screening rates," said Mike Gladstone, Global President of Internal Medicine at Pfizer.

Under the terms of the amended agreement, Pfizer will provide sales and marketing support through the end of 2022 and health system support through the end of 2021. Exact Sciences will compensate Pfizer based on the amount of services provided, along with additional fixed and performance-related fees set forth in the agreement. Exact Sciences will maintain responsibility for all aspects of manufacturing and laboratory operations of Cologuard.

More information about the agreement is available here, in a form 8-K that Exact Sciences has filed with the Securities and Exchange Commission.

About Cologuard
Cologuard was approved by the FDA in August 2014, and results from Exact Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society’s (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use Cologuard if you have had precancer, have inflammatory bowel disease and certain hereditary syndromes, or have a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. Cologuard performance in repeat testing has not been evaluated.

The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for diagnostic colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again.

Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer

On October 7, 2020 Achilles Therapeutics ("Achilles"), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, reported the appointment of Professor Karl Peggs as Chief Medical Officer (CMO) with effect from 4th January 2021 (Press release, Achilles Therapeutics, OCT 7, 2020, View Source [SID1234568179]). Professor Peggs is an internationally recognised leader in the field of cancer immunology and a founder of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Karl is a pioneer in the field of cancer immunology and has an unparalleled reputation for execution of complex cellular therapy trials," said Dr Iraj Ali, CEO of Achilles Therapeutics. "He was instrumental in the formation of Achilles and we are delighted that he will be joining the Company on a permanent basis. We are at an exciting time in our growth as we continue to expand our studies in non-small cell lung cancer and melanoma, whilst broadening our pipeline into other solid tumour indications."

"Achilles’ innovative platform, which enables the development of personalised T cell therapies for solid tumours targeting clonal neoantigens, has produced a uniquely compelling pipeline with the potential to target a broad range of cancers not satisfactorily addressed by currently approved therapies," said Professor Karl Peggs, Chief Medical Officer of Achilles Therapeutics. "I am thrilled to be working with the dynamic team at Achilles to execute on our vision of fundamentally changing how certain cancers are treated."

Karl is currently a Professor of Transplant Science and Cancer Immunotherapy at UCL Cancer Institute, Scientific Director of the NIHR Blood and Transplant Research Unit for Stem Cells and Immunotherapies, and Clinical and Scientific Director of the Sir Naim Dangoor Centre for Cellular Immunotherapy at UCLH. Karl received his preclinical training and MA at Cambridge University, completing his clinical training at Oxford University Medical School. He completed his general medical training at Addenbrooke’s Hospital Cambridge, and specialist haematology training at the John Radcliffe Hospital, Oxford and subsequently UCLH, London. He spent over 2 years at Memorial Sloan Kettering Cancer Center NYC, USA in the laboratory of Professor James Allison studying murine models of regulatory checkpoint blockade and subsequently ran a joint Research Laboratory with Professor Sergio Quezada at the UCL Cancer Institute where his research interests included viral infections, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics and he and Sergio retain active links to the institute. More recently he has established the clinical translational side of the academic CAR T cell programme at UCLH.

Wed, 07 Oct, 2020, 08:15 – English – Year-End Report 19/20

On October 7, 2020 Diamyd Medical AB (publ), reported that Fiscal year 2019/2020 (Press release, Diamyd Medical, OCT 7, 2020, View Source;ClipID=3792493 [SID1234568178])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Significant effect of Diamyd demonstrated in a large predefined patient group, covering about 40-50 percent of all type 1 diabetes patients

Figures in parentheses relate to the corresponding period previous financial year.

September 1, 2019 – August 31, 2020

Net result: MSEK 9.7 (-36.6), whereof fourth quarter MSEK -13.5 (-9.8). The increase compared to previous year is a one-off effect due to a payment of corresponding MSEK 48.0 from the previous GAD65 manufacturer as support for transition of the manufacturing process.
Result per share: SEK 0.1 (-0.5), fourth quarter SEK -0.2 (-0.1)
Cash flow from operating activities: MSEK 16.2 (-39.2), fourth quarter: MSEK -7.9 (-10.6)
Cash and cash equivalents at August 31, 2020: MSEK 68.4 (56.7). After the reporting period, MUSD 13.9 corresponding to MSEK 120 was received from divestment of shares in Companion Medical.
Significant events fourth quarter, June 1, 2020–August 31, 2020

A Remygen clinical trial was expanded to evaluate prevention of hypoglycaemia
Companion Medical Inc., in which Diamyd Medical is a shareholder, was announced to be acquired by Medtronic plc
Results highlighting efficacy of the diabetes vaccine Diamyd in genetically defined groups of type 1 diabetes patients were published in the scientific journal Diabetologia
Significant events after the reporting period

Diamyd Medical received USD 13.9 million after divestment in Companion Medical
Phase IIb topline results demonstrated a significant treatment effect of Diamyd in a predefined genetic patient group covering about 40-50% of all type 1 diabetes patients
Analyses of prevention trials and intralymphatic pilot trial with the diabetes vaccine Diamyd supported a positive efficacy trend in genetically defined groups of type 1 diabetes patients

Comments by CEO Ulf Hannelius
On September 14 we had the pleasure to announce the topline results from DIAGNODE-2, the European multicenter Phase IIb trial in 109 individuals recently diagnosed with type 1 diabetes. The results show, in line with comprehensive insights from previous trials and scientific publications, that the diabetes vaccine Diamyd (GAD-alum) has a positive and significant disease-modifying effect on the preservation of endogenous insulin production compared to placebo in a genetically predefined patient group. The focus forward into Phase III and beyond is aligned with genetics-based Precision Medicine – targeting the right individual with the right treatment at the right time.

Specifically and importantly, the topline results from DIAGNODE-2 make it clear that to receive a significant treatment benefit with Diamyd one should target individuals with HLA-type DR3-DQ2. Equally, there seems to be no benefit in individuals that do not present with this HLA type. These results are in line with the large scale meta study that we first announced in December 2019 and later were published this August in Diabetologia. That study showed that based on data from more than 500 patients from three placebo-controlled trials, the HLA-type significantly influences the effect of Diamyd and a positive effect is seen in individuals carrying the specific HLA type DR3-DQ2.

The notion of targeting individuals with HLA DR3-DQ2 is further supported by a combined analysis of two investigator-initiated prevention trials, DiaPrevIT-1 and DiaPrevIT-2, that we press released in August this year. While the individual trials did not support a benefit of Diamyd to prevent or prolong time to diagnosis in healthy at-risk children, the combined analysis showed a clear trend that the preventive benefit of Diamyd is seen in individuals that are positive for HLA DR3-DQ2. We also now know that the three individuals who all received a significant benefit following a fourth intralymphatic booster injection in the pilot trial DIAGNODE-1 were HLA DR3-DQ2 positive.

Furthermore, these results make sense from a scientific perspective. HLA DR3-DQ2 has previously been associated with autoimmunity against GAD, the active component in Diamyd. This is significant as the HLA region codes for the molecules that bind and present antigens to antigen reactive immune cells, a central mechanism regulating immunity that now is shown to be susceptible for immunomodulation and the target for therapeutic antigen-specific vaccines like Diamyd.

It should also be emphasized that despite the COVID-19 pandemic, DIAGNODE-2 has not met with any operational disruptions, which is a true testament to the safety and convenience of the treatment as well as to the competence and engagement of the clinics and collaborators involved in the trial. A safe, convenient, and effective disease- modifying treatment is imperative to reach therapeutic and commercial success in the type 1 diabetes field.

Going forward, the detailed results from DIAGNODE-2 will be published in a scientific journal and we are accelerating our design efforts for a pivotal Phase III trial. This trial will incorporate all the knowledge around Diamyd and especially the HLA aspect and the administration route, and we are planning interactions with the FDA to align the trial design and evaluate potential expedited regulatory pathways for Diamyd.

To summarize, it has been a truly pivotal year for Diamyd Medical.

Stockholm, October 7, 2020
Ulf Hannelius, President and CEO

Significant events during the fourth quarter

June 1, 2020 – August 31, 2020

Clinical trial with Remygen was expanded to evaluate prevention of hypoglycaemia
The Swedish Medical Products Agency approved an amendment to ReGenerate-1 to investigate Remygen’s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.

Medtronic announced plans to acquire Companion Medical
Companion Medical, Inc. of which Diamyd Medical is a shareholder, and Medtronic plc, jointly announced the acquisition of Companion Medical by Medtronic.

Results published highlighting efficacy of the diabetes vaccine Diamyd in genetically defined groups of type 1 diabetes patients
Diabetologia (the journal of the European Association for the Study of Diabetes EASD) published results from a meta study that demonstrates a highly significant and clinically relevant effect of Diamyd Medical’s lead drug candidate Diamyd (GAD-alum) on preserving endogenous insulin production in genetically defined groups of type 1 diabetes patients. The meta study, first reported in December 2019, comprises more than 500 patients from three placebo controlled randomized clinical trials conducted in Europe and the USA assessing the therapeutic diabetes vaccine Diamyd. The publication is co-authored by Dr. Ulf Hannelius, Diamyd Medical, Professor Craig Beam, Western Michigan University and Professor Johnny Ludvigsson, Linköping University.

Significant events after the reporting period

Diamyd Medical received USD 13.9 million in connection with divestment in Companion Medical
In connection with the previously announced acquisition of Companion Medical, Inc. by Medtronic plc., Diamyd Medical received approximately USD 13.9 million, corresponding to SEK 120 million. Depending on achievement of certain future milestones, some additional payments may be possible, and will then be communicated if they occur.

Phase IIb topline results demonstrated a significant treatment effect of Diamyd in a predefined genetic patient group covering about 40-50% of all type 1 diabetes patients
Diamyd Medical announced the topline results from the placebo-controlled Phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd (GAD-alum) was injected directly into a lymph node in individuals with recently diagnosed type 1 diabetes. In line with previous large-scale analysis of trials involving subcutaneous administration of Diamyd, the results, encompassing a total of 109 patients, showed a statistically significant effect in the predefined HLA (Human Leukocyte Antigen) group of trial participants. Specifically, this trial demonstrated a preservation of beta cell function at 15 months post-diagnosis, as measured by meal stimulated C-peptide. The primary endpoint, defined as meal stimulated C-peptide in the entire trial population was not met. Importantly, no related severe adverse events were observed in the trial. Based on these results, Diamyd Medical will pursue the HLA restricted responder group in an upcoming pivotal Phase III program.

Analyses of prevention trials and intralymphatic pilot trial with the diabetes vaccine Diamyd supported a positive trend in genetically defined groups of type 1 diabetes patients
A combined analysis of two previous clinical prevention trials, DiAPREV-IT 1 and 2 in healthy children at high risk of type 1 diabetes, as well as additional insights from the open label pilot trial DIAGNODE-1 in children and young adults newly diagnosed with type 1 diabetes, while not reaching statistical significance, were consistent with the recently published large-scale responder analysis which showed a highly significant and clinically relevant effect of the diabetes vaccine Diamyd in individuals positive for genotypes that include HLA DR3-DQ2.

Two drugs in clinical development

Diamyd and Remygen are drugs in clinical development that focus on the underlying disease mechanisms of diabetes; the dysfunction and loss of insulin-producing beta cells in the pancreas.

Diamyd is an antigen-specific immunomodulating diabetes vaccine for the treatment and prevention of autoimmune diabetes (type 1 diabetes and LADA, Latent Autoimmune Diabetes in Adults).

Clinical data indicate the potential of the diabetes vaccine Diamyd to halt or stop the autoimmune destruction of insulin-producing beta cells. The effect is achieved by antigen-specific reprogramming of immune cells by administration of low doses of Diamyd in superficial lymph nodes.

By maintaining the endogenous insulin production, Diamyd has the potential to make a significant difference in the daily life of patients as well significantly reduce the complications of type 1 diabetes.
Topline results from the Phase IIb trial DIAGNODE-2 has demonstrated a significant treatment effect of Diamyd in a predefined genetic patient group.

Remygen is an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune- and type 2 diabetes.By stimulating the growth of insulin-producing cells, Remygen has the potential to reverse the disease progression in autoimmune- and type 2 diabetes. Based on clinical data, Remygen has also the potential to protect against hypoglycemia by improving the hormonal response.

Remygen is now being investigated in a clinical Phase I/II trial (ReGenerate-1), where clinical efficacy is evaluated with the aim of optimizing the treatment regimen ahead of registration-based trials.

Ongoing clinical trials

Type 1 diabetes is a devastating disease which requires daily treatment with insulin to sustain life. The importance of finding a drug that improves the prospects for patients with diabetes is of utmost importance. The effect of intralymphatic administration of Diamyd, an antigen-specific immunotherapy aimed at stopping the immune system’s attack on insulin-producing beta cells in autoimmune diabetes, is evaluated in the Phase IIb trial DIAGNODE-2 and in the Phase II trial GADinLADA.

Remygen, which aims to stimulate the growth of beta cells in patients with diabetes, is evaluated in patients in a Phase I/II trial.

Trials with Diamyd in lymph node

DIAGNODE -2 – DIAMYD IN LYMPH NODES WITH ORAL SUPPLEMENTATION OF VITAMIN D
A follow-up double-blind randomized clinical trial where Diamyd is administered directly into a lymph node with oral supplements of vitamin D. The trial encompasses 109 patients from Sweden, the Czech Republic, Spain and the Netherlands, aged 12–24 years who have recently been diagnosed with type 1 diabetes. The 15-month results were presented on September 14, 2020, demonstrating a significant treatment effect of Diamyd in a predefined patient group. As of autumn 2019, patients who had not yet completed their last visit at 15 months were offered to participate in an extension of the trial for another 9 months. 53 patients agreed to participate in the extension trial and 15 of these patients have already been followed for 24 months. Results of this extended trial should be available in Q3 2021. Coordinating Investigator is Professor Johnny Ludvigsson at Linköping University, Sweden. Diamyd Medical is the Sponsor of the trial.

GADinLADA – DIAMYD IN LYMPH NODES WITH ORAL SUPPLEMENTATION OF VITAMIN D
An open-label, investigator initiated clinical trial where Diamyd is administered directly into a lymph node with oral supplements of vitamin D. The trial, conducted in Norway and in Sweden, encompasses 15 patients aged 30-70 years diagnosed with LADA (Latent Autoimmune Diabetes in Adults) and not yet on inulin treatment. The aim with the trial is to evaluate the safety of intralymphatic treatment with Diamyd in LADA patients and to continuously evaluate the immunological and clinical response during a one-year period. Sponsor of the trial is the Norwegian University of Science and Technology with Ingrid K Hals as sponsor representative.

Trial with Remygen (GABA)

REGENERATE-1 – REMYGEN /ALPRAZOLAM
An open-label, investigator initiated clinical trial with Remygen. The trial includes approximately 36 patients aged 18-50 who have had type 1 diabetes for more than five years with low to non-existing insulin production. Safety and initial efficacy results from the dose escalation section of the trial have paved the way to initiate the main trial and have also demonstrated a potential effect of Remygen to improve the hormonal response to hypoglycemia. The main trial evaluates whether the insulin-producing cells can be regenerated and if the hormonal response to hypoglycaemia can be improved using Remygen and the combination of Remygen and Alprazolam. The trial is led by Professor Per-Ola Carlsson at Uppsala University, Sponsor of the trial.

Manufacturing of GAD65 in Umeå
A new facility for vaccine manufacturing is being set up in Umeå, the Capital of Västerbotten County in Sweden, for the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the therapeutic diabetes vaccine Diamyd currently in late-stage clinical development The 10 000 square feet site, comprising of clean rooms, laboratory facilities and office space, will facilitate full control, predictability and scalability of the manufacturing technology of the active ingredient.

Novalgen licenses mAbsolve’s QumAb™ technology to improve the safety of therapeutic antibodies

On October 6, 2020 NovalGen reported that a new generation of antibody variant developed by mAbsolve has been licensed to Novalgen for evaluation in their pipeline of therapeutic antibodies for treatment of cancer, leukaemias and cardiovascular disease (Press release, NovalGen, OCT 6, 2020, View Source [SID1234633769]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

QumAb is a small variation to the natural antibody structure which eliminates the unwanted inflammatory responses often associated with antibody therapy. In some situations, these responses are beneficial, but often they lead to unpleasant, even dangerous side-effects.

Previous work met with some success, and today about 50% of therapeutic antibodies in development include some sort of alteration to mitigate unwanted side-effects. However, these approaches do not solve the problem completely. QumAb builds on this previous work to provide a complete Fc-silencing solution with excellent manufacturability properties.

Dr Ian Wilkinson, inventor of the QumAb technology, said: "After working with numerous pharma and biotech companies using the earlier methods with limited success, I became convinced that a better solution was possible. I went back to first principles to design and screen a large panel of variants from which QumAb was discovered. I am delighted that in such a short time the new technology is being taken into commercial development."

Prof Geoff Hale, CEO of mAbsolve, said: "I have devoted my career to the development of therapeutic antibodies, and while we saw some success, many promising antibody drugs were discarded because of unacceptable levels of inflammatory response. QumAb is the best solution to this problem that I have seen and I am thrilled to be working with Novalgen as the first adopter of this new technology."

Mr Nilesh Modi, COO of Novalgen, said: "I’m delighted to be working with the newly formed mAbsolve team, who individually have fantastic track records. Licensing the QumAb antibody silencing solution will add to our array of technologies and we hope will help us develop safer antibody therapies, and will deliver the life-changing treatments that many patients desperately need.."

Prof Amit Nathwani, CEO and Founder of Novalgen. Professor of Haematology, University College London said: "The QumAb technology represents a significant advance and will help NovalGen develop life changing therapeutics for a range of disorders with unmet clinical need. We are excited to be working in partnership with mAbsolve."

Prof Kerry Chester, Chief Scientific Officer of Novalgen and Professor of Molecular Medicine, University College London said: "We are thrilled to be early adopters of the QumAb Fc-silencing technology. I have every confidence in the mAbsolve team and believe that QumAb technology will be a critical part of new antibody-based therapies."